EGFR and non-small cell lung carcinoma: Reduced antibody titers against SARS-CoV-2 and trends to lower levels of antigen-secreting cells were identified in NSCLC patients with EGFR mutations who received TKIs compared to those undergoing ALK-directed therapy.